Reports Q4 revenue $3.958B, consensus $3.93B. Reports: Adjusted EBITDA of $996 M for the fourth quarter, $3,684 Mfor the full year;R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x ;R&D Solutions contracted backlog of $31.1 billion, up 5.5 percent year-over-year at constant currency. “IQVIA (IQV) delivered excellent fourth quarter performance, closing out a strong 2024,” said Ari Bousbib, chairman and CEO of IQVIA. “R&DS revenue was on target and bookings exceeded our expectations despite the choppy CRO market environment. TAS revenue was above target and momentum continues to build into 2025. For the full year, we delivered margin expansion, high single-digit growth in Adjusted EPS, and outstanding free cash flow; we also repurchased $1.35 billion dollars of our shares while lowering our net leverage ratio year-over-year. We are reaffirming the 2025 guidance we provided at our December Investor Day.”
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio